GoodRx reports Q4 revenue $194.8M, Adj. EBITDA $65.0M; Pharma Direct grows >40% YoY for 2025

GoodRx Holdings, Inc.

2025-FY EPS reported $0.09 revenue$796,853,000

Q4 2025 revenue $194.8M, net income $5.4M, Adjusted EBITDA $65.0M (33.4% margin).
Full-year 2025 revenue $796.9M, net income $30.4M, Adjusted EBITDA $270.5M (33.9% margin).
Pharma Direct revenue beat prior outlook with over 40% year-over-year growth in 2025.
CEO Wendy Barnes notes strong finish, rebranded Pharma Manufacturer Solutions as Pharma Direct.
Adjusted Net Income Q4 $29.0M (14.9% margin); FY $126.1M (15.8% margin).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.